What Matters Now
CME
Making Treatment Decisions in Early Alzheimer’s Disease: Biomarkers, ARIA, and When to Start Therapy
Pierre Tariot, MD, Banner Alzheimer’s Institute
Dani Cabral, MD, BrainLove
73% of Peers Changed Their Practice After this Clinical Scenario
CME
A 71-year-old with positive plasma p-tau217 but no confirmatory amyloid PET or CSF faces DMT consideration amid incomplete diagnostic certainty and undefined ARIA risk.
What Matters Now
CME
Making Treatment Decisions in Early Alzheimer’s Disease:
Biomarkers, ARIA, and When to Start Therapy
Pierre Tariot, MD, Banner Alzheimer’s Institute
Dani Cabral, MD, BrainLove
Corresponding Scenario
Biomarker Results Are Back: Is the Evidence Strong Enough to Confirm Alzheimer's Pathology?
See experiences from 88 peers
A 71-year-old with positive plasma p-tau217 but no confirmatory amyloid PET or CSF faces DMT consideration amid incomplete diagnostic certainty and undefined ARIA risk.
How clinicians responded after this Clinical Scenario
75
%
begin unsure how to apply evidence
73
%
will implement a practice change
